8-K: Incannex Healthcare Appoints Dr. Alison Wimms to OSA Clinical Advisory Board

Incannex Healthcare appoints Alison Wimms, Ph.D., representing ResMed, to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board.

Summary

• Incannex Healthcare has appointed Alison Wimms, Ph.D., to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board.
• Dr. Wimms brings two decades of sleep medicine industry and research expertise to the role.
• She will represent ResMed on the advisory board.
• Incannex is currently conducting a Phase 2/3 clinical trial (RePOSA) for IHL-42X, an oral fixed-dose combination of acetazolamide and dronabinol, for the treatment of OSA.
• A top-line readout from the U.S. Phase 2 portion of the RePOSA trial is expected in the first half of 2025.
• In a prior Australian Phase 2 clinical trial, IHL-42X reduced the Apnea-Hypopnea Index (AHI) by an average of 51 percent relative to baseline at the lowest dose.

Sentiment

Score: 7

Explanation: The announcement is positive due to the addition of an experienced advisor and the progress of the IHL-42X clinical trial. However, the forward-looking statements and associated risks temper the overall sentiment.

Positives

• The appointment of Dr. Wimms adds significant expertise to Incannex's OSA clinical advisory board.
• The ongoing Phase 2/3 RePOSA clinical trial represents a significant step in the development of IHL-42X for OSA treatment.
• Prior Phase 2 trial results showed a 51% reduction in AHI with the lowest dose of IHL-42X.
• The expansion of the Phase 3 portion of the RePOSA trial to include sites in the United Kingdom and European Union increases the scope of the study.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include the continued availability of financing, the ability to raise capital, the success of development efforts, and competition from other providers and products.

Future Outlook

Incannex anticipates a top-line readout from the U.S. Phase 2 portion of the RePOSA clinical trial in the first half of 2025.

Management Comments

• Joel Latham, Incannex's President and Chief Executive Officer, stated that the appointment of Dr. Wimms underscores the company's continued dedication to innovation in the field of OSA.
• Dr. Alison Wimms stated that she is excited to join Incannex's OSA Clinical Advisory Board and looks forward to advising on IHL-42X late-stage clinical development.

Industry Context

The appointment of Dr. Wimms, who represents ResMed, a major player in sleep apnea treatment, suggests a potential collaboration or partnership in the future development and commercialization of IHL-42X. This is a positive sign for Incannex as it seeks to establish itself in the competitive sleep apnea market.

Comparison to Industry Standards

• ResMed (NYSE: RMD, ASX: RMD) is a global leader in sleep apnea devices and digital health solutions.
• Incannex's IHL-42X aims to provide an alternative treatment option for patients who are non-compliant, intolerant, or naive to positive airway pressure devices like CPAP, which are ResMed's primary products.
• The 51% reduction in AHI observed in the prior Phase 2 trial is a promising result compared to other pharmacological interventions for OSA, but further data from the Phase 2/3 RePOSA trial is needed to confirm these findings.

Stakeholder Impact

• Shareholders may view the appointment of Dr. Wimms and the progress of the IHL-42X clinical trial as positive developments.
• Patients with OSA may benefit from the development of IHL-42X as an alternative treatment option.

Next Steps

• Incannex will continue the Phase 2/3 RePOSA clinical trial.
• The company anticipates a top-line readout from the U.S. Phase 2 portion of the RePOSA trial in the first half of 2025.

Key Dates

Keywords

Incannex Healthcare, Alison Wimms, Obstructive Sleep Apnea, IHL-42X, Clinical Advisory Board, ResMed, RePOSA, Acetazolamide, Dronabinol, OSA